Cronos Group (CRON)
(Delayed Data from NSDQ)
$2.16 USD
-0.04 (-1.82%)
Updated Oct 15, 2024 04:00 PM ET
After-Market: $2.15 -0.01 (-0.46%) 5:16 PM ET
3-Hold of 5 3
C Value A Growth C Momentum B VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$2.16 USD
-0.04 (-1.82%)
Updated Oct 15, 2024 04:00 PM ET
After-Market: $2.15 -0.01 (-0.46%) 5:16 PM ET
3-Hold of 5 3
C Value A Growth C Momentum B VGM
Zacks News
Analysts Estimate Cronos Group (CRON) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Cronos (CRON) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zacks Market Edge Highlights: Aurora Cannabis, Canopy Growth, Cronos Group, Innovative Industrial Properties and Constellation Brands
by Zacks Equity Research
Zacks Market Edge Highlights: Aurora Cannabis, Canopy Growth, Cronos Group, Innovative Industrial Properties and Constellation Brands
Is it Finally Time to Buy Marijuana Stocks?
by Tracey Ryniec
With new states set to legalize cannabis this November, and the possibility of federal legalization looming, will the marijuana stocks finally live up to the hype?
Company News for Aug 7, 2020
by Zacks Equity Research
Companies In The News: BMY, CRON, BDX, LNG.
Cronos Group (CRON) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Cronos (CRON) delivered earnings and revenue surprises of -216.67% and 16.96%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
Analysts Estimate Cronos Group (CRON) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Cronos (CRON) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Cronos (CRON) to Report Q2 Earnings: What's in the Offing?
by Zacks Equity Research
Investors will focus on regular top and bottom-line numbers along with its pipeline progress, when Cronos (CRON) reports Q2 results.
Is it Time to Buy Cannabis Stocks & ETFs?
by Neena Mishra
CNBC's cannabis expert Tim Seymour discusses the outlook for the industry.
Is Cronos Group (CRON) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Is (CRON) Outperforming Other Medical Stocks This Year?
Cronos Group's Shares March Higher, Can It Continue?
by Zacks Equity Research
As of late, it has definitely been a great time to be an investor in Cronos Group.
Cronos (CRON) Looks Good: Stock Adds 8.1% in Session
by Zacks Equity Research
Cronos (CRON) saw a big move last session, as its shares jumped more than 8% on the day, amid huge volumes.
Find Stocks Under $10 to Buy Amid Coronavirus Economic Reopening
by Benjamin Rains
We screened for strong 'cheap' stocks that are trading under $10 a share that investors might want to buy as the market rally continues...
Cronos Group (CRON) Beats Q1 Earnings Estimates
by Zacks Equity Research
Cronos (CRON) delivered earnings and revenue surprises of 385.71% and -21.68%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
Cronos (CRON) to Report Q1 Earnings: What's in the Offing?
by Zacks Equity Research
Investors will focus on regular top and bottom-line numbers along with its pipeline progress, when Cronos (CRON) reports Q1 results.
Earnings Preview: Cronos Group (CRON) Q1 Earnings Expected to Decline
by Zacks Equity Research
Cronos (CRON) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Cronos Group (CRON) Gains As Market Dips: What You Should Know
by Zacks Equity Research
Cronos Group (CRON) closed at $5.52 in the latest trading session, marking a +1.85% move from the prior day.
Cronos Group (CRON) Reports Q4 Loss, Lags Revenue Estimates
by Zacks Equity Research
Cronos (CRON) delivered earnings and revenue surprises of -75.00% and -36.86%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?
Here's How Coronavirus Can Impact Cannabis Industry
by Zacks Equity Research
Marijuana should be avoided during the pandemic as users share marijuana joints, which may increase the spread of the virus.
Cronos (CRON) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
Investors will focus on Cronos' (CRON) regular top- and bottom-line numbers, along with its pipeline progress, when it reports Q4 results.
What Do Canopy Earnings Say About Cannabis ETFs?
by Sanghamitra Saha
Solid earnings drive Canopy Growth stock and boost the industry as a result. Is it right time to buy marijuana ETFs?
Cronos Group (CRON) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
Cronos Group (CRON) closed at $7.13 in the latest trading session, marking a -0.7% move from the prior day.
What's in Store for Pot Stocks This Year?
by Nitish Marwah
Increasing tolerance, financial protection, credit availability and legal votes have shaped America's hemp industry lately.
Will Cronos Group Continue to Surge Higher?
by Zacks Equity Research
As of late, it has definitely been a great time to be an investor Cronos Group
Cronos (CRON) in Focus: Stock Moves 5.1% Higher
by Zacks Equity Research
Cronos (CRON) saw a big move last session, as its shares jumped more than 5% on the day, amid huge volumes.
What's Ahead for Marijuana ETFs After a Dismal Show in 2019?
by Sanghamitra Saha
Marijuana ETFs hit a high in 2018 only to experience a bloodbath in 2019. Let's see what lies in store for the space in 2020.